Logo

CLBT

Cellebrite DI Ltd.

CLBT

Cellebrite DI Ltd. • NASDAQ
$16.86 ▲ 0.18% (+0.03)
Market Cap $4.12 B
52w High $26.30
52w Low $13.10
Dividend Yield 0%
P/E 44.37
Volume 380.65K
Outstanding Shares 244.47M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $126.029M ▲ $86.725M ▲ $20.189M ▲ 16.019% ▼ $0.083 ▲ $26.991M ▲
Q2-2025 $113.276M ▲ $81.182M ▲ $19.476M ▲ 17.193% ▲ $0.081 ▲ $17.009M ▲
Q1-2025 $107.549M ▼ $77.791M ▲ $17.4M ▼ 16.179% ▼ $0.07 ▼ $14.899M ▼
Q4-2024 $109.049M ▲ $75.698M ▲ $19.269M ▲ 17.67% ▲ $0.083 ▲ $18.456M ▼
Q3-2024 $106.858M $71.969M $-207.093M -193.802% $-0.99 $22.067M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $525.712M ▲ $834.319M ▲ $386.634M ▲ $447.685M ▲
Q2-2025 $472.184M ▲ $787.425M ▲ $379.012M ▲ $408.413M ▲
Q1-2025 $409.486M ▼ $709.892M ▲ $346.398M ▼ $363.494M ▲
Q4-2024 $447.223M ▲ $690.567M ▲ $354.547M ▲ $336.02M ▲
Q3-2024 $370.763M $629.246M $330.93M $298.316M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $20.189M ▲ $33.272M ▲ $63.788M ▲ $5.267M ▼ $102.138M ▲ $29.95M ▲
Q2-2025 $19.476M ▲ $32.583M ▲ $40.577M ▲ $13.826M ▲ $88.748M ▲ $28.975M ▲
Q1-2025 $17.4M ▼ $20.878M ▼ $-126.504M ▼ $3.62M ▼ $-101.184M ▼ $18.539M ▼
Q4-2024 $19.269M ▲ $65.967M ▲ $-15.949M ▲ $6.73M ▲ $55.31M ▲ $61.65M ▲
Q3-2024 $-207.093M $41.65M $-18.665M $5.528M $29.393M $39.83M

Five-Year Company Overview

Income Statement

Income Statement Revenue has grown steadily over the last several years, and the core business now generates solid gross profit. Operating profitability has gradually improved from roughly break-even to clearly positive, which suggests better cost control and scale. However, bottom-line net income has been inconsistent: the company moved from profits to losses again in the most recent years. That pattern usually points to non-operating items or one‑off charges weighing on reported earnings, even as the underlying operations get stronger. Overall, the top line and operating trends look constructive, but the volatility in net income adds some uncertainty to reported results and earnings per share.

Balance Sheet

Balance Sheet The balance sheet looks much healthier than a few years ago. Total assets have expanded, cash reserves are meaningful, and debt is very low relative to the size of the business. Shareholders’ equity has swung from negative to comfortably positive, indicating a cleaner capital structure and a stronger financial cushion. The big step-up in equity in the latest year likely reflects capital infusions or accounting adjustments. In plain terms, the company appears better capitalized and less financially fragile than it used to be, though investors should understand what drove the recent equity jump.

Cash Flow

Cash Flow Cash generation is a relative bright spot. The business has consistently produced positive operating cash flow for several years, and that cash flow has been trending upward. Investment needs for property and equipment are modest, so free cash flow has remained positive and improving. The company is not dependent on external funding to cover its day‑to‑day operations, which lowers financial risk. The combination of stable cash balances, low capital spending, and recurring free cash flow suggests a business model that converts a good portion of revenue into real cash.

Competitive Edge

Competitive Edge Cellebrite sits in a specialized niche—digital forensics and digital intelligence—where it is widely viewed as a reference player, especially for law enforcement and government agencies. Its tools are deeply embedded in customer workflows, and many users hold Cellebrite-specific certifications, which makes switching to competitors costly and disruptive. The company’s broad device coverage, strong brand recognition in legal and investigative circles, and integrated “case-to-closure” platform create meaningful barriers to entry. That said, this market is sensitive to regulation, public policy, and budget cycles, which can influence demand and pricing power over time.

Innovation and R&D

Innovation and R&D Innovation is at the heart of Cellebrite’s strategy. It has built an end‑to‑end platform that stretches from device data extraction to AI‑driven analytics and secure evidence management. Continuous updates to support new devices and apps, along with advanced unlocking capabilities, require sustained R&D investment. The acquisition of Corellium adds deeper virtualization and security research capabilities, which could strengthen the technology stack and open new use cases. Ongoing work in artificial intelligence, cloud delivery, and remote data collection for enterprises suggests a roadmap aimed at staying ahead of both criminals and competing vendors, though the payoff from these initiatives will depend on execution and customer adoption.

Summary

Cellebrite combines a strengthening underlying business with still‑uneven reported profits. Revenue and operating performance have improved, cash flow is solid and consistently positive, and the balance sheet is now stronger with low leverage and higher equity. Strategically, the company holds a leading position in a niche, mission‑critical market, reinforced by high switching costs, specialized certifications, and a reputation as a standard setter in digital forensics. Its innovation agenda—especially around AI, cloud, and virtualization—offers room for further growth in both public-sector and enterprise markets. The main areas to watch are the drivers of net income volatility, the impact of regulatory and budget environments on demand, and the company’s ability to successfully integrate new technologies like Corellium into commercially successful products.

NEWS

November 12, 2025 · 4:01 PM UTC

Cellebrite Announces Third-Quarter 2025 Results

Read more

October 30, 2025 · 8:30 AM UTC

Cellebrite Appoints Holly Windham as General Counsel and Chief Compliance Officer

Read more

October 17, 2025 · 9:00 AM UTC

Cellebrite to Report Third-Quarter 2025 Financial Results on November 12, 2025

Read more

October 15, 2025 · 8:30 AM UTC

Cellebrite Expands Market Reach with Innovations in Agentic AI, Cloud and Device Virtualization for the Company's Autumn 2025 Release

Read more